Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned
Open Access
- 26 May 2009
- journal article
- Published by Wiley in Acta Ophthalmologica
- Vol. 87 (4) , 450-454
Abstract
: Loss of vision in primary open‐angle glaucoma (glaucoma) is caused by retinal ganglion cells dying at a seemingly steady and variable rate in different patients. Present treatments for all glaucoma patients are inadequate and a goal to rectify this is to discover appropriate drugs or chemicals (neuroprotectants) that can be taken orally to slow down retinal ganglion cell death and have negligible side‐effects. It was therefore of great disappointment to learn earlier this year that the one clinical trial conducted to test the efficacy of memantine as a neuroprotectant for glaucoma was unsuccessful. In this article, I consider the mechanisms by which retinal ganglion cells may die in glaucoma and suggest that memantine may have benefited patients taking it but to a level that was difficult to detect with present methodologies. Ganglion cells are induced to die by different triggers in glaucoma, suggesting that neuroprotectants with multiple modes of actions are likely to reveal clearer results than was found for memantine. Therefore, the idea of neuroprotection in glaucoma must not be abandoned.Keywords
This publication has 36 references indexed in Scilit:
- What Is the Present Pathogenetic Concept of Glaucomatous Optic Neuropathy?Survey of Ophthalmology, 2007
- Risk Factors and Open-angle Glaucoma: Classification and ApplicationJournal of Glaucoma, 2007
- The chemical biology of clinically tolerated NMDA receptor antagonistsJournal of Neurochemistry, 2006
- Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamateNature Neuroscience, 2004
- The impact of ocular blood flow in glaucomaProgress in Retinal and Eye Research, 2002
- Inherited neurodegenerative diseases: the one-hit model of neurodegenerationHuman Molecular Genetics, 2001
- A one-hit model of cell death in inherited neuronal degenerationsNature, 2000
- Elevated Glutamate Levels in the Vitreous Body of Humans and Monkeys With GlaucomaArchives of Ophthalmology (1950), 1996
- Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicityThe Journal of Neuroscience, 1992
- Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channelsEuropean Journal of Pharmacology, 1989